What are the limitations of the cervical cancer staging?

While the cervical cancer staging is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the cervical cancer staging to ensure safe bedside use and optimal diagnostic accuracy.

How does the cervical cancer staging compare to other Obstetrics scores?

The cervical cancer staging is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the cervical cancer staging free to use?

Yes. OpiCalc provides the cervical cancer staging completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

Cervical Cancer Staging

FIGO Cervical Staging (2018)

Validated Oncology Framework

Confined to Cervix

IA (<5mm depth) | IB (IB1 <2cm, IB2 2-4cm, IB3 ≥4cm)

Beyond Uterus (No Pelvic Wall)

IIA (Upper 2/3 Vagina) | IIB (Parametrial involvement)

III

Lower Vagina / Pelvic Wall

IIIA (Lower 1/3 Vagina) | IIIB (Pelvic Wall/Hydronephrosis) | IIIC (Lymph Nodes)

Bladder / Rectum / Distant

IVA (Adjacent organs) | IVB (Distant Metastasis)

Note: Clinical, imaging, and pathological findings are all used for formal staging since 2018.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Clinical Uses

Global standard for staging cervical carcinoma to determine prognosis
Triage tool distinguishing surgical candidates from definitively chemoradiation-treated patients
Universal research criteria for gynecologic oncology clinical trials

The 2018 Paradigm Shift

Prior to 2018, cervical cancer staging was strictly clinical (allowing access in low-resource environments). The 2018 update fundamentally changed this, integrating advanced imaging (MRI/PET) and surgical pathology to assign stage, recognizing that clinical palpation vastly understages lymph node involvement.

CLINICAL INSIGHT

How it Works

Stage I — Confined to the Cervix

IA1

IA2

IB1

IB2

IB3

Stage II — Beyond Uterus, not to Pelvic Wall/Lower Vagina

IIA1

IIA2

IIB

Stage III — Pelvic Wall, Lower Vagina, Lymph Nodes

IIIA

IIIB

IIIC1

IIIC2

Stage IV — Adjacent/Distant Spread

IVA

IVB

CLINICAL INSIGHT

Practical Pearls

Crucial Lymph Node Rules

Lymph node involvement instantaneously upgrades ANY primary tumor to Stage IIIC.
If a 1 cm tumor (IB1) has positive pelvic nodes on MRI, it is recorded as Stage IIIC1, totally bypassing Stage I/II classifications.
Notation is highly specific: Use "r" if staged by imaging (e.g., IIIC1r) and "p" if staged by pathology (e.g., IIIC1p).

CLINICAL INSIGHT

Next Steps

Management Pathways (General Guidelines)

IA1 to IB2: Generally candidates for primary surgical management (e.g., radical hysterectomy +/- pelvic lymph node dissection). Fertility-sparing trachelectomy possible in highly selected IA-IB1.
IB3 and IIA2 (Bulky local disease): Institutional highly debated; usually defaults to primary concurrent chemoradiation.
IIB through IVA: Definitive concurrent cisplatin-based chemoradiotherapy is the gold standard.
IVB: Systemic chemotherapy (carboplatin/paclitaxel) + Bevacizumab + Pembrolizumab (if PD-L1 positive).

CLINICAL INSIGHT

Evidence Base

The 2018 Update Publication

Revised FIGO staging for carcinoma of the cervix uteri.

Bhatla N, Berek JS, Cuello Fredes M, et al.Int J Gynaecol Obstet.2019

CLINICAL INSIGHT

Background

FIGO

The International Federation of Gynecology and Obstetrics (FIGO) Committee on Gynecologic Oncology continuously revises staging criteria to ensure they reflect modern diagnostic capabilities and therapeutic outcomes.

Cervical Cancer Staging

FIGO Cervical Staging (2018)

Validated Oncology Framework

Confined to Cervix

IA (<5mm depth) | IB (IB1 <2cm, IB2 2-4cm, IB3 ≥4cm)

Beyond Uterus (No Pelvic Wall)

IIA (Upper 2/3 Vagina) | IIB (Parametrial involvement)

III

Lower Vagina / Pelvic Wall

IIIA (Lower 1/3 Vagina) | IIIB (Pelvic Wall/Hydronephrosis) | IIIC (Lymph Nodes)

Bladder / Rectum / Distant

IVA (Adjacent organs) | IVB (Distant Metastasis)

Note: Clinical, imaging, and pathological findings are all used for formal staging since 2018.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Clinical Uses

Global standard for staging cervical carcinoma to determine prognosis
Triage tool distinguishing surgical candidates from definitively chemoradiation-treated patients
Universal research criteria for gynecologic oncology clinical trials

The 2018 Paradigm Shift

CLINICAL INSIGHT

How it Works

Stage I — Confined to the Cervix

IA1

IA2

IB1

IB2

IB3

Stage II — Beyond Uterus, not to Pelvic Wall/Lower Vagina

IIA1

IIA2

IIB

Stage III — Pelvic Wall, Lower Vagina, Lymph Nodes

IIIA

IIIB

IIIC1

IIIC2

Stage IV — Adjacent/Distant Spread

IVA

IVB

CLINICAL INSIGHT

Practical Pearls

Crucial Lymph Node Rules

Lymph node involvement instantaneously upgrades ANY primary tumor to Stage IIIC.
If a 1 cm tumor (IB1) has positive pelvic nodes on MRI, it is recorded as Stage IIIC1, totally bypassing Stage I/II classifications.
Notation is highly specific: Use "r" if staged by imaging (e.g., IIIC1r) and "p" if staged by pathology (e.g., IIIC1p).

CLINICAL INSIGHT

Next Steps

Management Pathways (General Guidelines)

IA1 to IB2: Generally candidates for primary surgical management (e.g., radical hysterectomy +/- pelvic lymph node dissection). Fertility-sparing trachelectomy possible in highly selected IA-IB1.
IB3 and IIA2 (Bulky local disease): Institutional highly debated; usually defaults to primary concurrent chemoradiation.
IIB through IVA: Definitive concurrent cisplatin-based chemoradiotherapy is the gold standard.
IVB: Systemic chemotherapy (carboplatin/paclitaxel) + Bevacizumab + Pembrolizumab (if PD-L1 positive).

CLINICAL INSIGHT

Evidence Base

The 2018 Update Publication

Revised FIGO staging for carcinoma of the cervix uteri.

Bhatla N, Berek JS, Cuello Fredes M, et al.Int J Gynaecol Obstet.2019

CLINICAL INSIGHT